Staloral 300

Package leaflet: Information for the patient

STALORAL 300
Plant-derived allergen extracts (pollens)
House dust mite allergen extracts
Allergen extract mixtures
Sublingual solution
10 IR/ml; 300 IR/ml
Read the following information carefully before using this medicine, as it contains
important information for the patient.

• Keep this leaflet for future reference.
• If you have any questions, consult your doctor, pharmacist, or nurse.
• This medicine has been prescribed for a specific individual. Do not pass it on to others. It may harm someone else, even if their symptoms are similar.
• If you experience any adverse reactions, including those not listed in this leaflet, inform your doctor, pharmacist, or nurse. See section 4.

Leaflet contents

1. What STALORAL 300 is and what it is used for
2. Important information before using STALORAL 300
3. How to take STALORAL 300
4. Possible side effects
5. How to store STALORAL 300
6. Contents of the pack and other information

1. What STALORAL 300 is and what it is used for

STALORAL 300 is an allergen-specific immunotherapy medicinal product. It is used in patients allergic to plant-derived allergens (pollens) or house dust mite allergens, the list of which is included in the annex to this leaflet.
Indications
Allergic diseases with seasonal or perennial symptoms, including rhinitis (sneezing, runny or itchy nose, nasal congestion), conjunctivitis (itchy, watery eyes), or asthma (mild or moderate), in adults and children (over 5 years of age).
The aim of treatment with STALORAL 300 is to increase immunological tolerance to allergens and thereby reduce allergic reactions.

2. Important information before using the medicinal product STALORAL 300

When not to use STALORAL 300

• if the patient has hypersensitivity (allergy) to any of the other components of STALORAL 300 (see section 6);
• if the patient has immune system disorders or diseases;
• if the patient has a malignant (cancerous) disease;
• if the patient has severe or uncontrolled asthma;
• if the patient has oral cavity inflammation.

Only a physician can determine whether there are contraindications to the use of this medicinal product.
Warnings and precautions
Before starting treatment, allergic symptoms should be stabilized with appropriate symptomatic treatment, if necessary.
Before initiating treatment with STALORAL 300, inform your doctor or pharmacist:

• if the patient has severe clinical symptoms of allergy at the time treatment is to begin – treatment should be postponed;
• if the patient has recently suffered from other illnesses or if allergy symptoms have recently worsened;
• if the patient is scheduled for oral surgery or tooth extraction. Treatment with STALORAL 300 should be interrupted until the oral cavity has completely healed;
• if the patient currently has or has previously had eosinophilic esophagitis;
• if during treatment the patient develops severe or persistent abdominal pain, difficulty swallowing, or chest pain;
• if the patient is on a strict low-sodium diet, because the medicinal product contains sodium (see section "STALORAL 300 contains sodium chloride");
• if the patient is taking medications from the beta-blocker group (including eye drops or ointments).

STALORAL 300 and other medicinal products
Inform your doctor about all medicinal products you have recently taken, including those available without a prescription.
Before starting treatment, inform your doctor:

• if the patient is taking certain antidepressants (tricyclic antidepressants or monoamine oxidase inhibitors - MAOIs), as there is an increased risk of adverse reactions if epinephrine (administered in case of severe allergic reactions) needs to be used, even with potentially fatal outcomes;
• if the patient is scheduled for preventive vaccination against infectious diseases. Vaccination can be performed without interrupting treatment, but only after evaluation of the patient's general health status.

Symptomatic treatment (e.g., with antihistamines and/or intranasal corticosteroids) may be used concomitantly with STALORAL 300.
Pregnancy and breastfeeding
Patients who are pregnant, suspect they may be pregnant, or plan to become pregnant should consult a doctor or pharmacist before using this medicinal product.
Patients who are breastfeeding should consult a doctor or pharmacist before using this medicinal product.
There is no experience regarding the use of STALORAL 300 in pregnant or breastfeeding women; therefore, immunotherapy should not be initiated in pregnant or breastfeeding women unless considered necessary by the physician.
Patients who become pregnant or start breastfeeding during treatment with STALORAL 300 should consult their doctor regarding continuing treatment.
Driving and operating machinery
There are no contraindications to driving or operating machinery during treatment with STALORAL 300.
STALORAL 300 contains sodium chloride.
For patients on a low-sodium diet, the presence of sodium chloride in the product should be taken into account (one vial - 10 ml of solution contains 590 mg of sodium chloride). See section "Warnings and precautions".
3. How to use STALORAL 300
Recommended dose
STALORAL 300 must always be used according to the doctor's instructions. In case of doubt, consult your doctor or pharmacist again. If a higher dose of STALORAL 300 than recommended is used or if a dose of STALORAL 300 is missed, read the information in the appropriate sections of the package leaflet.
Specific immunotherapy is most effective when initiated early in the course of the disease.
The dose does not depend on age but on the individual patient's level of reactivity.
In seasonal allergies, treatment should be started before the pollen season and continued until the end of the pollen season.
In perennial allergies, treatment should be continued throughout the year.
Treatment consists of two phases:

• initial treatment phase – with gradually increasing dose
• maintenance treatment phase – with a constant dose.

Allergen solutions of different concentrations are used in treatment, with vials distinguished by cap color:
Cap color: blue – concentration 10 IR/ml
Cap color: violet – concentration 300 IR/ml
Initial treatment with dose escalation
The dose of the medicinal product should be administered under the tongue by pressing the pump dispenser; after 2 minutes, it should be swallowed.
The medicinal product is used daily, with the dose gradually increased until the maintenance dose is reached, according to the following schedule:

The above dosing regimen should be considered as a guideline and example of treatment. Treatment may be modified depending on the patient's condition and their response to therapy.
Maintenance treatment – fixed dose
The maximum, well-tolerated dose should be taken daily or three times a week.
The recommended dosing regimen is at least 4 actuations three times a week or 2 to 4 actuations taken daily, using a solution with a concentration of 300 IR/ml.
Clinical studies using STALORAL 300 with various allergens have shown that a daily dose of 300 IR is well tolerated.
Duration of treatment
Allergen-specific immunotherapy is generally administered for a period of 3 to 5 years.
The physician will reassess the treatment if there is no significant improvement in symptoms after one year (for perennial allergy) or after the first pollen season (for seasonal allergy).
Method of administration
To ensure safe use of the medicinal product, it is essential to strictly follow the physician’s instructions.
STALORAL 300 is administered sublingually.
Before taking the medicine, carefully check the information on the packaging and confirm that the details match the physician’s prescription: composition and concentration of the medicine, as well as the expiry date.
The medicine should be taken during the day, on an empty stomach, without food or drink.
The dose should be administered under the tongue by pressing the pump dispenser plunger; after 2 minutes, it should be swallowed.
The physician may recommend a different dosing regimen depending on the patient’s condition and their response to treatment.
STALORAL 300 should be administered to children by an adult.
Instructions for first use:
At first use, follow the steps below:

1. Remove the colored plastic part of the cap.
2. Pull the metal tab and completely remove the aluminum seal.
3. Remove the grey stopper.
4. Remove the dosing pump from its plastic housing. Place the vial on a flat surface and, holding it firmly with one hand, press the pump firmly into place.
5. Remove the purple protective ring.
6. Prime the pump by repeatedly pressing the pump plunger. After 5 actuations, the pump delivers one full dose of the medicine.
7. Place the tip of the dosing pump into the mouth, directly under the tongue. Press firmly to deliver one full dose. Repeat the procedure to administer the number of doses prescribed by the physician. Hold the solution under the tongue for 2 minutes, then swallow.
8. After use, clean the tip of the dosing pump and replace the protective ring.
9. For subsequent uses, remove the protective ring and repeat steps 7 and 8.

7
Allergen-specific immunotherapy is generally administered for 3 to 5 years. In the case of seasonal allergy, specific immunotherapy may be continued over several consecutive pollen seasons.
Use in children
Allergen immunotherapy is not recommended for children under 5 years of age.
Use of a higher than recommended dose of STALORAL 300
Inform your physician or pharmacist immediately.
If a higher than recommended dose is used, the risk of experiencing a greater number or more severe adverse effects increases.
Missed dose of STALORAL 300
Do not take a double dose to make up for a missed dose.
Continue treatment the next day by taking the prescribed dose.
Discontinuation of STALORAL 300
If STALORAL 300 is discontinued for less than one week, treatment may be continued using the last dose. If treatment is interrupted for longer than one week, contact your physician.
If you have any further questions regarding the use of this medicine, consult your physician, pharmacist, or nurse.

4. Possible adverse reactions

Like all medicines, this medicine can cause adverse reactions, although not everyone will experience them.
During treatment with STALORAL 300, the patient will be exposed to substances that
may cause allergic reactions at the site of administration and/or symptoms affecting the whole body.
Such reactions may occur at the beginning of treatment or later, during treatment.
STALORAL 300 must be discontinued immediately and medical help sought if
any of the following symptoms occur or are noticed:
Severe allergic reaction with rapid onset of symptoms affecting the whole body, e.g.
intense itching or rash, difficulty breathing, abdominal pain, or symptoms related to
low blood pressure, such as dizziness, feeling unwell.
Tolerance to a given dose may change over time depending on the patient's health status and environment.
If an adverse reaction occurs, the patient should consult a physician, who may
adjust the treatment regimen.
The physician may prescribe pre-treatment with antiallergic medications to reduce the
frequency and severity of adverse reactions.

Additional adverse reactions
Common (affects less than 1 in 10 patients)
Oral cavity disorders (e.g. swelling, discomfort, tingling, itching, numbness, blisters, ulcers), tongue swelling, discomfort in the throat or pain, swelling or irritation, rhinitis (stuffy nose, runny nose, sneezing, itchy nose, nasal discomfort), cough, salivary gland disorders, itchy eyes, itchy ears, nausea, vomiting, abdominal pain, diarrhoea, skin redness or itching.

Uncommon (affects less than 1 in 100 patients)
Eye disorders (redness, eye irritation, watery eyes), herpes, hoarseness, breathing difficulties, asthma, urticaria, atypical skin allergic symptoms (burning, tingling, pricking), gastritis, oesophageal spasms.

Rare (affects less than 1 in 1000 patients)
Headache, eczema, joint pain, muscle pain, weakness, enlarged lymph nodes (glands), fever.

The following adverse reactions have also been reported:
Taste disturbances, dry mouth sensation, dizziness, facial swelling, severe allergic reactions, oesophagitis.

Reporting of adverse reactions
If any adverse reactions occur, including any adverse reactions not listed in this leaflet, inform your doctor, pharmacist, or nurse. Adverse reactions can be reported directly to the Department of Monitoring of Adverse Drug Reactions, Office for Registration of Medicinal Products, Medical Devices and Biocidal Products, Al. Jerozolimskie 181C
02-222 Warszawa
tel. 22 49 21 301, fax. 22 49 21 309,
Website: https://smz.ezdrowie.gov.pl
Adverse reactions can also be reported to the marketing authorization holder.
Reporting adverse reactions allows further information on the safety of the medicine to be collected.

5. How to store STALORAL 300

The medicine should be stored out of sight and reach of children.
Before opening: Store in the refrigerator (2°C - 8°C).
After opening:
10 IR/ml: Store in the refrigerator (2°C - 8°C) for up to 30 days.
300 IR/ml: Store below 25°C for up to 30 days or in the refrigerator (2°C - 8°C) for up to 30 days.
During transport, vials must always be kept in an upright position.
Do not use this medicine for longer than 30 days after opening or after the expiry date stated on the carton after EXP. The expiry date refers to the last day of the stated month.
Medicines must not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help protect the environment.

6. Contents of the pack and other information

What STALORAL 300 contains

The active substances are allergen extracts or their mixtures at concentrations of 10 or 300 IR/ml (according to Annex 1), in combination with mannitol. The amount of mannitol does not exceed 40 mg/ml.
The qualitative composition of the active substance may be individually selected for the patient from the allergens listed in Annex 1.
The activity of the relevant allergen expressed in IR*/ml units is indicated on the label.
* IR (Index of Reactivity): An allergen extract has an activity of 100 IR/ml if, in a skin prick test using the Stallerpoint lancet, it produces a wheal with a diameter of 7 mm in 30 individuals sensitized to that allergen.
Additionally, the sensitivity of these individuals is confirmed by a positive reaction to 9% codeine phosphate or histamine dihydrochloride at a concentration of 10 mg/ml in a skin prick test.

Other ingredients: sodium chloride, glycerol, purified water.

What STALORAL 300 looks like and contents of the pack

Maintenance treatment set:
3 vials of 10 ml each (concentration 10 IR/ml, concentration 300 IR/ml, concentration 300 IR/ml)

• 3 metering pumps

Maintenance treatment set:
2 vials of 10 ml each (concentration 300 IR/ml, concentration 300 IR/ml)

• 2 metering pumps

Marketing Authorisation Holder and Manufacturer

STALLERGENES
6, rue Alexis de Tocqueville
92160 Antony, France

For further information, contact the local representative of the Marketing Authorisation Holder in Poland:
STALLERGENES Sp. z o.o.
tel. 22 620 29 98

STALORAL 300 ANNEX 1

I. PLANT-DERIVED ALLERGEN EXTRACTS (PLANT POLLENS)

Grasses and cereals:
661 Timothy grass (Phleum pratense)

Trees:
609 Alder (Alnus glutinosa)
615 Birch (Betula alba)
651 Olive tree (Olea europaea)
649 Hazel (Corylus avellana)

II. HOUSE DUST MITE ALLERGEN EXTRACTS
315 Dermatophagoides pteronyssinus
314 Dermatophagoides farinae

III. MIXTURES OF ALLERGEN EXTRACTS

Plant-derived:
688 5 grasses (timothy grass, sweet vernal grass, perennial ryegrass, meadow fescue, timothy grass)

House dust mites:
350 Dermatophagoides pteronyssinus, Dermatophagoides farinae